- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05248555
Het nationale Australische HCV Point-of-Care-testprogramma - Minimale gegevensset
Het nationale Australische HCV Point-of-Care-testprogramma: een observationele cohortstudie om het gebruik van point-of-care hepatitis C-testen met vingerprik te evalueren om de diagnose en behandeling van HCV-infectie te verbeteren - Minimale dataset
The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). All participants who undergo HCV point-of-care testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The advent of simple direct-acting antiviral hepatitis C (HCV) therapies with cure rates >95% is one of the greatest medical advances in decades, having led to a reversal in liver-related mortality. In Australia, treatment uptake has declined between 2016 (32,000 treated) and 2019/20 (2019: 11,500; 2020: 8,500).1 Progress towards HCV elimination has been impeded by COVID-19, affecting the delivery of national and state-based HCV strategies. Improving HCV treatment uptake to reduce disease burden is a key aim of global, national and state-based HCV strategies.2-4
Scale-up of HCV testing and treatment will be required to achieve elimination by 2030. Current diagnostic pathways require multiple visits to a practitioner reducing the proportion who receive a diagnosis. In Australia, 81% of people have had HCV antibody testing (indicates exposure), but only 47% have been HCV RNA tested (indicates active infection and the need for HCV treatment).5 Mathematical modelling suggests that HCV RNA testing needs to increase by at least 50% annually to achieve elimination in Australia by 2030.6
The Kirby Institute is an international leader in research evaluating the Xpert HCV assay (Grebely Lancet Gastro Hep 2017), having built a large network of Xpert platforms for HCV testing in needle and syringe programs, prisons, drug treatment clinics, tertiary hospitals, and Aboriginal Community Controlled Health Service. In Kirby-led research, point-of-care HCV testing interventions in needle and syringe programs and prisons have resulted in high HCV treatment uptake (70-90%). The Kirby Institute and Flinders University also have a strong track record of implementing point-of-care testing for STIs and COVID-19, providing an ideal foundation to scale-up Xpert HCV testing in Australia.
The Kirby Institute and Flinders University will establish the Australian National HCV Point-of-care Testing Program for the scale-up of point-of-care HCV RNA testing in services with high prevalence of HCV infection, including community health centres, drug treatment clinics, needle and syringe programs, and prisons. This program will include the development of standard operating procedures, logistics/deployment, initial set-up, an operator training program, and quality assurance and competency assessment program.
An observational cohort study will be established to evaluate HCV treatment uptake following scale-up of point-of-care HCV testing among people with a risk factor for acquisition of HCV infection or people attending a service caring for people with risk factors for the acquisition of HCV infection.
Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection. All participants who undergo point-of-care HCV testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care for any other clinical assessments and treatment initiation.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Simon Comben, BSc, MN
- Telefoonnummer: +6193480777
- E-mail: scomben@kirby.unsw.edu.au
Studie Contact Back-up
- Naam: David Silk, BSc
- Telefoonnummer: +61293850900
- E-mail: dsilk@kirby.unsw.edu.au
Studie Locaties
-
-
New South Wales
-
Sydney, New South Wales, Australië
- Actief, niet wervend
- Justice Health and Forensic Mental Health Network
-
-
Queensland
-
Aldershot, Queensland, Australië, 4650
- Werving
- Maryborough Correctional Centre
-
Contact:
- Ashley Willman
- Telefoonnummer: (07) 4123 7600
- E-mail: ashley.willmann@health.qld.gov.au
-
Brisbane, Queensland, Australië, 4000
- Werving
- QuIHN
-
Contact:
- Nicholas Alexander
- Telefoonnummer: 3620 8111
- E-mail: nalexander@quihn.org
-
Cairns, Queensland, Australië
- Werving
- Lotus Glen Correctional Centre
-
Contact:
- Darren Russell
-
Hoofdonderzoeker:
- Darren Russell
-
Coorparoo, Queensland, Australië, 4151
- Voltooid
- Hepatitis Queensland
-
Ipswich, Queensland, Australië
- Werving
- West Moreton Hospital and Health Service
-
Contact:
- Blake Ponting
-
Hoofdonderzoeker:
- Blake Ponting
-
Rathdowney, Queensland, Australië, 4287
- Nog niet aan het werven
- Palen Creek Correctional Centre
-
Contact:
- Mike Hurley
- Telefoonnummer: (07) 5544 3700
- E-mail: mike.hurley@corrections.qld.gov.au
-
Townsville, Queensland, Australië
- Werving
- Townsville Correctional Centre
-
Contact:
- John Morey
-
Hoofdonderzoeker:
- John Morey
-
Woodford, Queensland, Australië
- Werving
- Woodford Correctional Centre
-
Contact:
- Rajendra Prakash
-
Hoofdonderzoeker:
- Rajendra Prakash
-
-
South Australia
-
Hackney, South Australia, Australië, 5069
- Werving
- Hepatitis SA
-
Contact:
- Lisa Carter
- Telefoonnummer: (08) 8362 8443
- E-mail: lisa@hepatitissa.asn.au
-
Marden, South Australia, Australië, 5070
- Nog niet aan het werven
- South Australian Prison Health Service
-
Contact:
- Tom Turnbull
-
Hoofdonderzoeker:
- Tom Turnbull
-
Mount Gambier, South Australia, Australië, 5290
- Werving
- Mount Gambier Priosn
-
Contact:
- William Galloway
-
Hoofdonderzoeker:
- William Galloway
-
-
Victoria
-
Fitzroy, Victoria, Australië, 3065
- Actief, niet wervend
- St Vincent's Correctional Health Services
-
Melbourne, Victoria, Australië, 3000
- Werving
- Medically Supervised Injecting Room
-
Contact:
- Nathan Stam
-
Hoofdonderzoeker:
- Nathan Stam
-
Ravenhall, Victoria, Australië, 3023
- Werving
- Dame Phyllis Frost Centre
-
Contact:
- Katelyn Mannix
- Telefoonnummer: 1300 492 202
- E-mail: katelyn.mannix@wh.org.au
-
Ravenhall, Victoria, Australië, 3023
- Werving
- Geo Healthcare - The Geo Group Australia Pty Ltd
-
Contact:
- David Grace
-
Hoofdonderzoeker:
- David Grace
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection, including drug treatment clinics, needle and syringe programs, prisons, mobile outreach services, community health services, mental health services, homelessness services, and other appropriate settings nationally. It is anticipated approximately 40,000 participants will be screened for HCV infection using point-of-care HCV testing.
Beschrijving
Inclusion Criteria:
- ≥ 18 years of age.
- Received point-of-care HCV testing.
Exclusion Criteria:
- Nil
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
People at risk of HCV acquisition
Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing. |
Participants will be offered finger-stick point-of-care testing for HCV |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The proportion of HCV infected participants who initiate HCV treatment at 12 weeks
Tijdsspanne: 12 Weeks from enrolment
|
To evaluate the proportion of HCV infected (HCV RNA quantifiable) participants who initiate HCV treatment at 12 weeks following finger-stick point-of-care HCV RNA testing. |
12 Weeks from enrolment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The proportion of participants who accept point-of-care testing
Tijdsspanne: 2 years from recruitment commencement
|
To evaluate the proportion of people who accept point-of-care testing among those offered testing. |
2 years from recruitment commencement
|
|
The prevalence of HCV infection amongst study participants tested
Tijdsspanne: 2 years from recruitment commencement
|
To evaluate the prevalence of current HCV infection (HCV RNA quantifiable) among people tested. |
2 years from recruitment commencement
|
|
To evaluate the time to HCV treatment uptake among HCV RNA positive participants
Tijdsspanne: 52 weeks
|
To evaluate the length of time participants take to initiate HCV treatment after diagnosis |
52 weeks
|
|
To evaluate proportion of HCV RNA positive participants who initiate HCV treatment
Tijdsspanne: 52 weeks
|
To evaluate the proportion of HCV RNA positive participants who initiate HCV treatment at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing. |
52 weeks
|
|
To evaluate the proportion of participants who complete HCV (DAA) treatment
Tijdsspanne: 52 weeks
|
To evaluate the proportion of participants who complete HCV direct-acting antiviral (DAA) treatment. |
52 weeks
|
|
To evaluate the proportion of participants who achieve an SVR
Tijdsspanne: 12 weeks
|
To evaluate the proportion of participants who achieve an SVR (defined as HCV RNA below the lower limit of quantitation at post treatment week 12). |
12 weeks
|
|
To evaluate the proportion of participants who are HCV RNA negative at 12 months
Tijdsspanne: 52 weeks
|
To evaluate the proportion of participants who are HCV RNA negative at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing. |
52 weeks
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- VHCRP2104
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Request to share IPD will be considered by the protocol steering committee on individual basis
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .